EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors

K. Papadopoulos, T. Li, N. Lakhani, J. Powderly, T. George, D.G.K. Teoh, D. Kilari, G. Giaccone, R.E. Sanborn, S. Ghamande, P. LoRusso, G. Gibney und 8 weitere

Immuno-Oncology and Technology · 2022-12 · 16 · 100284

DOI: 10.1016/j.iotech.2022.100284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immuno-Oncology and Technology, 2022-12. Verfasst von K. Papadopoulos und 19 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

JTX-8064, a highly selective and potent IgG4 inhibitor of myeloid-specific Leukocyte Immunoglobulin Like Receptor B2 (LILRB2), leads to macrophage reprogramming from an immunosuppressive to an immune activated state, resulting in T cell activation. INNATE (NCT04669899) is a phase (P) 1/2 dose escalation/expansion study of two investigational agents, JTX-8064 monotherapy (mono) and combination (combo) with pimi. P1 data defining Recommended P2 Dose (RP2D) are presented.

Zitieren

APA

Papadopoulos, K., Li, T., Lakhani, N., Powderly, J., George, T., Teoh, D., Kilari, D., Giaccone, G., Sanborn, R., Ghamande, S., LoRusso, P., Gibney, G., Ma, V., Yalamanchili, K., Brown, J., Mota, N., Kadra, C. T., Umiker, B., Xiao, X., & Trehu, E. (2022). 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. Immuno-Oncology and Technology, 16, 100284. https://doi.org/10.1016/j.iotech.2022.100284

Vancouver

Papadopoulos K, Li T, Lakhani N, Powderly J, George T, Teoh D, et al. 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. Immuno-Oncology and Technology. 2022;16:100284. doi:10.1016/j.iotech.2022.100284

BibTeX
@article{Papadopoulos2022,
  author = {Papadopoulos, K. and Li, T. and Lakhani, N. and Powderly, J. and George, T. and Teoh, D.G.K. and Kilari, D. and Giaccone, G. and Sanborn, R.E. and Ghamande, S. and LoRusso, P. and Gibney, G. and Ma, V.T-L. and Yalamanchili, K. and Brown, J. and Mota, N. and Kadra, C. Tasillo and Umiker, B. and Xiao, X. and Trehu, E.},
  title = {172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors},
  journal = {Immuno-Oncology and Technology},
  year = {2022},
  volume = {16},
  pages = {100284},
  doi = {10.1016/j.iotech.2022.100284}
}
Kostenlos starten →